Hong Kong · Delayed Price · Currency is HKD InnoCare Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 55.5% year-over-year to RMB 1.14 billion, with net profit reaching RMB 240 million and strong cash reserves supporting R&D. Multiple late-stage assets advanced in oncology and autoimmune diseases, with several NDAs and phase III studies underway. Guidance for over 35% full-year drug sales growth reaffirmed.
Fiscal Year 2025
-
Achieved first annual profit and 135% revenue growth, driven by strong product sales and major BD deals. Robust pipeline progress in oncology and autoimmune diseases, with multiple regulatory approvals and global partnerships. Drug sales expected to grow over 35% in 2026.
-
Revenue grew 74.3% year-over-year in H1 2025, driven by strong drug sales and new approvals. Net loss narrowed by 86.7%, and the company maintains a robust cash position to support global R&D and commercialization. Multiple late-stage assets and strategic partnerships are set to drive future growth.
Fiscal Year 2024
-
Orelabrutinib sales grew 49.1% year-over-year, driving a 30% reduction in annual loss and strong cash reserves. Multiple late-stage assets advanced, including NDAs for CLL/SLL and Tafasitamab, while the ADC platform and TYK2 inhibitors showed promising progress.
-
Orelabrutinib drove strong sales and margin growth in Q3 2024, with total loss narrowing by 47.1% year-over-year and robust cash reserves supporting ongoing R&D and pipeline expansion. Multiple phase 3 trials and regulatory milestones were achieved, with continued focus on autoimmune and hemato-oncology markets.
-
Strong H1 2024 revenue growth was driven by orelabrutinib, with improved margins and reduced losses. Multiple clinical and regulatory milestones were achieved, and robust cash reserves support long-term growth, with break-even targeted by 2027–2028.